NS5A inhibitors distinguish half-life differences between HCV strains
Researchers at the University of North Carolina (Chapel Hill, NC, USA) have identified how NS5A inhibitors interact with hepatitis C virus, and their findings show a difference between strains of HCV, which could help provide more effective therapies against a broader range of viruses.
Please sign in or register for FREE
Sign in to MedChemNet
Register to MedChemNet – the medicinal chemistry network
MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.